Buscar
01/03/2026
B cell depletion and BAFF receptor blockade with ianalumab (VAY736) for the treatment of moderate-to-severe systemic lupus erythematosus: a phase 2 randomised, double-blind, placebo-controlled trial with subsequent open-label treatment
Agmon-Levin, N, Ignatenko, S, Gordienko, A, Cortés-Hernández, J, Narongroeknawin, P, Romanowska-Próchnicka, K, Shen, N, Ciferska, H, Kodera, M, Cheng-Chung, WJ, Leszczynski, P, Lan, JL, Mysler, E, Wojciechowski, R, Tarr, T, Vishneva, E, Chen, YH, Kaneko, Y, Finzel, S, Hoi, A, Okada, M, Koolvisoot, A, Lee, SS, Lie, D, Kaneko, H, Rojkovich, B, Sun, LY, Zotkin, E, Viallard, JF, López, BPM, Ghanshani, SA, Lau, C, Avrameas, A, Sips, C, Oliver, SJ. B cell depletion and BAFF receptor blockade with ianalumab (VAY736) for the treatment of moderate-to-severe systemic lupus erythematosus: a phase 2 randomised, double-blind, placebo-controlled trial with subsequent open-label treatment. ANNALS OF THE RHEUMATIC DISEASES. 2026; 85(3)DOI:10.1016/j.ard.2025.11.015. PMID:41353079. IF:20.600(Q1/1D).
01/03/2026
Switching from Originator Tocilizumab to Biosimilar in Giant Cell Arteritis: Evaluation of Effectiveness and Safety in a Multicenter Cohort of 38 Patients
Loricera, J, Molina-Collada, J, Nieto, JC, Sánchez-Lucas, M, Silva-Díaz, MT, Moya, P, Labrador, E, Ferraz-Amaro, I, Blanco, R. Switching from Originator Tocilizumab to Biosimilar in Giant Cell Arteritis: Evaluation of Effectiveness and Safety in a Multicenter Cohort of 38 Patients. DRUGS & AGING. 2026; 43(3)DOI:10.1007/s40266-026-01281-1. PMID:41714460. IF:3.800(Q2/3D).
01/03/2026
Recommendations for the diagnostic, treatment, and follow-up of late-onset Pompe disease
Dominguez-González, C, Romero, MAB, Eraso, CC, de las Heras, J, Muñoz, EF, Garcia-Campos, O, González, M, Grau, JM, Hernández-Voth, A, Morales, RJ, Hernández, JCL, Martos, ML, López-Padilla, D, Muelas, N, Nascimento, A, Olivé, M, Paradas, C, Fernández, JP, Pascual, SI, Pitarch, I, Sancho, J, Diaz-Manera, J. Recommendations for the diagnostic, treatment, and follow-up of late-onset Pompe disease. NEUROLOGIA. 2026; 41(2)DOI:10.1016/j.nrl.2025.501933. PMID:41453611. IF:3.100(Q2/4D).
01/03/2026
Effect of Rituximab on Neurofilament Levels in CIDP: Results From the CIDPRIT Randomized Trial
Doneddu, PE, Collet-Vidiella, R, Gallo, C, Cocito, D, Manganelli, F, Falzone, Y, Dalla Bella, E, Benedetti, L, Mazzeo, A, Peci, E, Spina, E, Strano, C, Germano, F, Gentile, L, Liberatore, G, Cutellè, C, Bianchi, E, Querol, L, Nobile-Orazio, E. Effect of Rituximab on Neurofilament Levels in CIDP: Results From the CIDPRIT Randomized Trial. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2026; 31(1)DOI:10.1111/jns.70107. PMID:41649095. IF:3.200(Q2/4D).